The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia.

about

The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia.

Item

http://www.wikidata.org/entity/Q39306416

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia.

@en

The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia.

@nl

type

Item

label

The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia.

@en

The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia.

@nl

prefLabel

The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia.

@en

The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia.

@nl

P1476

The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia.

@en

P2093

Etienne Paubelle

http://www.w3.org/2001/XMLSchema#string

Florence Zylbersztejn

http://www.w3.org/2001/XMLSchema#string

Xavier Thomas

http://www.w3.org/2001/XMLSchema#string

P2860

Cellular roles of dna topoisomerases: a molecular perspective

Targeting DNA topoisomerase II in cancer chemotherapy

Acute Myeloid Leukemia

Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II

Reactive oxygen species-induced DNA damage and its modification: a chemical investigation

Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.

Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.

Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo.

P304

747-753

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17460441.2017.1331215

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28504025

http://www.w3.org/2001/XMLSchema#string

P921

leukemia